Tute Genomics

关于Tute Genomics

Tute Genomics是一个提供基于云的基因组分析解决方案，主要用来帮助研究人员解析从人类外显子组直至基因组的序列数据。公司成立于2013年7月，总部在美国。

Tute Genomics获得230万美金A轮融资

医谷编者案：之前医谷报道过《玩真的！谷歌整合Tute Genomics基因数据》，最近这家公司获得了融资。其在由英国泛欧洲发展资本Eurovestech领衔投资A轮融系列融资中获得了230万美元的融资。投资的参与者还有Peak Ventures 和一些未被提及的天使投资人。

TuteGenomics宣布这些资金将为今年种子期融资提供150万美元的资本。种子期投资方包括Wilmington Pharmatech、Salt Lake Life Science Angels、Salt Lake LifeScience Angels以及Park City Angel Network。Tute公司同时也通过融资平台AngelList取得了另外30万美元的注资。TuteCEO里德罗宾逊在一份声明中说：“我们将处在一个基因组测序技术被广泛运用于医疗保障的时代，下一代测序技术将引领该时代的到来，我们将寻求寻求基于这些技术的新方法来诊断、治疗和预防疾病。通过投资者的支持，我们将实现我们在转化医学领域的远大目标。”

Tute与 Advanced BiologicalLaboratories拥有在欧洲、非洲以及亚洲部分Tute业务平台的软件销售市场协议，并且与Lineagen达成协议来分析其对于儿童发展障碍的分子诊断测试结果。今年5月，该公司签约成为全球基因健康联盟成员.

Tute Genomics Acquires Knome

Procurement of highly acclaimed genome interpretation technology from Knome fortifies Tute Genomics’ mission to catalyze precision, genome-guided medicine.

PROVO, Utah, November 2, 2015 – Tute Genomics, the leader in clinical sequencing informatics, today announced the acquisition of key assets of Knome, a renowned human-genome interpretation company whose systems and services helped spearhead several of the greatest commercial advancements in modern human genetics.

Knome was co-founded in 2007 by renowned geneticist and Harvard professor George Church, who recognized a substantial need for genome interpretation technology as the cost of sequencing was rapidly decreasing. The company has received national recognition and become a vanguard in fields such as personal genomics and genome research services. In addition to providing genome sequencing and interpretation to individuals such as Ozzy Osbourne and other high profile early adopters, Knome’s most valuable technology is knoSYS, a best-in-class genome interpretation software platform. Now in its third generation of development, what began as genome analysis software for single human genomes nearly a decade ago, knoSYS has transformed into the most sophisticated genome interpretation and clinical decision support system available. Tute Genomics is integrating Knome’s knoSYS technology with Tute’s cloud-based genome informatics and clinical reporting platform, further bolstering the company’s ability to deliver the most comprehensive, flexible, scalable, and secure informatics solution for genome-guided medicine.

“Knome’s software is a testament to the extraordinary foresight and ingenuity of its scientists and engineers, as well as the remarkable amount of financial support the company has achieved over the years,” stated Reid Robison, MD, MBA, the CEO of Tute Genomics. “The result is a wealth of technology assets that are well-poised to tackle the bioinformatics challenges faced by healthcare, such as rapidly processing raw genome sequencing data, performing clinical interpretation of the data and generating actionable clinical reports. We are tremendously excited and honored to be in a position to offer clinical labs and health systems this pioneering technology integrated within Tute’s cloud-based genome informatics solution.”

Knome’s knoSYS technology brings maximum value to the already robust genome informatics offerings at Tute, used by many of the top laboratories, hospitals, and genomics facilities across the world. The company employs sample-in, report-out technology to enable users to process raw sequencing data, perform rigorous quality control measures, annotate genetic variants with over 200 of the most relevant genetic knowledge sources, and seamlessly create clinical reports. Tute has also been integrated with third party tools such as LIMS for scalable sample information management, and EHR systems to bring genetic insights to point-of-care and help guide every medical decisions throughout a patient’s life.

This groundbreaking transaction furthers Tute’s position as the leader in clinical genome informatics, allowing more health systems and clinical laboratories worldwide access to information that will make prevention, diagnosis, and treatment of disease more accessible than ever.

About Tute Genomics: Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a rapid and secure fashion. Tute is powering the world’s genomic knowledge through enterprise informatics, genome interpretation, and clinical insights. Genomics is changing healthcare as we know it, and Tute is shaping the future of medicine: unlocking the genome, personalizing treatment, and powering discovery. Tute is a StartupHealth and Healthbox portfolio company, and has received strategic investments from large institutions such as Intermountain Healthcare. To learn more please visit www.tutegenomics.com and follow us on Twitter @TuteGenomics.

About Knome, Inc.:Knome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome’s big data technologies are helping to smooth the healthcare industry’s transition to molecular-based, precision medicine.